Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
A phase 1/2 trial of Belantamab mafodotin, Nirogacestat in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Overview
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM is a phase 1/2 interventional study registered as NCT07084896 by GlaxoSmithKline, with 106 participants enrolled, started 2020-06-08 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Shares Nirogacestat, Belantamab mafodotin, GSK, Multiple myeloma.
- TrialStudy of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi
Shares Nirogacestat, Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Belantamab mafodotin, GSK, Multiple myeloma.